Mr. Trent Northcutt reports

AURORA SPINE CORPORATION CELEBRATES SECOND ANNIVERSARY OF INITIAL IMPLANTATION OF THE WORLD'S FIRST BONE DENSITY MATCHED DEXA-C CERVICAL INTERBODY FUSION DEVICE

Aurora Spine Corp. has completed the second full year of implantation of the world's first patient-bone-density matched interbody device, the cervical interbody Dexa-C.

Trent Northcutt, chief executive officer and president at Aurora Spine, said: "It's a significant milestone for Aurora to celebrate the second anniversary of the world's first surgical implantations of the Dexa-C patient-bone-density matched interbody devices. The Dexa-C implants, a line of cervical cages for anterior cervical discectomy with fusion (ACDF) procedures, are the first of its kind in the world offering an implant based upon a patient's bone density. It is also the first colour-coded implant on the marketplace and will help doctors match against the colour-coding of a Dexa score."

Dr. Sebastian Koga, neurosurgeon at Koga Neurosurgery in Covington, La., said: "After two years and over 200 levels with the Dexa-C cage, I could never go back to standard cages or structural allograft. My colleagues who have implanted the device, also feel the same. I am able to confidently offer multilevel anterior fusions to patients who likely could not have benefited from other existing implants because of their bone density. The interface between the woven lattice of the cage and the end plate images very clearly on X-ray and CT and causes reduced artefact on MRI."

Aurora announced in March, 2023, that it had received Institutional Review Board (IRB) approval for its new multicentre study of its Dexa-C cervical interbody system, which is indicated for anterior cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one or two contiguous levels from C2-T1.

In June, 2023, Aurora announced that the first patient has been enrolled for its multicentre study of Dexa-C cervical interbody system. The commencement of the enrolment of patients indicates that the company has received all necessary approvals to launch the study, with initial plans to include data from 40 single-level and 40 multiple-level subjects.

Dr. Koga continued: "We are reviewing the first 100 patients in a retrospective clinical study now, while also collecting prospective longitudinal data for the Dexa study. Preliminarily, we have seen both in radiographs and surgical exploration that patients have incipient bone fusion by 90 days after surgery. This technology is now ripe for duplication in more challenging areas of the spine. I continue to believe that that progress is contingent on new biomaterials, and that such personalized implants will revolutionize spine surgery."

In February, 2024, Aurora announced the issuance of its second United States Patent No. 11,850,162 entitled "Body Density Scan Result-Matched Orthopedic Implants and Methods of Use" for The World's First Dexa Technology patient-matched implant technology.

Aurora is focused on the release of other devices utilizing the patented Dexa technology. Mr. Northcutt stated, "These patents will allow us to create Dexa implants for use anywhere in the human body where bone fixation is needed providing patients with previously non-existing new treatment possibilities."

About Aurora Spine Corp.

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

We seek Safe Harbor.